Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib or Dasatinib in Previously Untreated Chronic Phase CML
NCT00070499Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2004
- Primary completion
- Nov 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of imatinib and dasatinib in chronic myeloid leukemia (CML) (3 arms), sponsored by National Cancer Institute. Primary endpoint: Molecular Response Rate at 12 Months. Started Aug 2004; status: active, not recruiting.
02
Drugs
imatinibdasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00070499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070499.